OBJECTIVE: To assess the effectiveness of cotrimoxazole preventive therapy (CPT) among individuals with CD4 cell count above 200 cells/microl and varying WHO clinical stages in reducing mortality during combination antiretroviral therapy (cART). DESIGN: A cohort study. METHODS: Using proportional hazards modeling, we compared mortality during the first 12 months after cART initiation among patients receiving CPT with patients not receiving CPT. We adjusted for clinic level confounding throughout. RESULTS: We included 14 097 patients starting cART between January 2003 and January 2008, 62% of whom were men, the median CD4 cell count was 132 cells/microl, and 1289 died (11%). The baseline median CD4 cell count was lower (118 vs. 153 cells/microl) among the 7508 patients who received CPT compared with the 6589 patients who did not. In adjusted multivariate modeling, stratifying for baseline CD4 cell count and WHO stage, CPT reduced mortality overall (hazard ratio 0.64, P < 0.001) and for all individuals with CD4 cell count below 200 cells/microl or WHO clinical stage 3 or 4 conditions but did not reduce mortality for patients with both CD4 cell count above 200 cells/microl and WHO clinical stage 1 or 2. CONCLUSION: We demonstrated a 36% reduction in mortality extending to patients associated with CPT when used with cART that extended to patients with CD4 cell count above 350 cells/microl in a setting with minimal malaria and high rates of cotrimoxazole-resistant bacteria. This provides important additional data toward efforts to increase CPT provision among all cART initiators in resource limited settings.
OBJECTIVE: To assess the effectiveness of cotrimoxazole preventive therapy (CPT) among individuals with CD4 cell count above 200 cells/microl and varying WHO clinical stages in reducing mortality during combination antiretroviral therapy (cART). DESIGN: A cohort study. METHODS: Using proportional hazards modeling, we compared mortality during the first 12 months after cART initiation among patients receiving CPT with patients not receiving CPT. We adjusted for clinic level confounding throughout. RESULTS: We included 14 097 patients starting cART between January 2003 and January 2008, 62% of whom were men, the median CD4 cell count was 132 cells/microl, and 1289 died (11%). The baseline median CD4 cell count was lower (118 vs. 153 cells/microl) among the 7508 patients who received CPT compared with the 6589 patients who did not. In adjusted multivariate modeling, stratifying for baseline CD4 cell count and WHO stage, CPT reduced mortality overall (hazard ratio 0.64, P < 0.001) and for all individuals with CD4 cell count below 200 cells/microl or WHO clinical stage 3 or 4 conditions but did not reduce mortality for patients with both CD4 cell count above 200 cells/microl and WHO clinical stage 1 or 2. CONCLUSION: We demonstrated a 36% reduction in mortality extending to patients associated with CPT when used with cART that extended to patients with CD4 cell count above 350 cells/microl in a setting with minimal malaria and high rates of cotrimoxazole-resistant bacteria. This provides important additional data toward efforts to increase CPT provision among all cART initiators in resource limited settings.
Authors: X Anglaret; G Chêne; A Attia; S Toure; S Lafont; P Combe; K Manlan; T N'Dri-Yoman; R Salamon Journal: Lancet Date: 1999-05-01 Impact factor: 79.321
Authors: S Z Wiktor; M Sassan-Morokro; A D Grant; L Abouya; J M Karon; C Maurice; G Djomand; A Ackah; K Domoua; A Kadio; A Yapi; P Combe; O Tossou; T H Roels; E M Lackritz; D Coulibaly; K M De Cock; I M Coulibaly; A E Greenberg Journal: Lancet Date: 1999-05-01 Impact factor: 79.321
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Christopher J Hoffmann; Katherine L Fielding; Victoria Johnston; Salome Charalambous; Craig Innes; Richard D Moore; Richard E Chaisson; Alison D Grant; Gavin J Churchyard Journal: J Acquir Immune Defic Syndr Date: 2011-11-01 Impact factor: 3.731
Authors: Heidi M Soeters; Anne von Gottberg; Cheryl Cohen; Vanessa Quan; Keith P Klugman Journal: Antimicrob Agents Chemother Date: 2012-01-09 Impact factor: 5.191
Authors: Christopher J Hoffmann; James J Lewis; David W Dowdy; Katherine L Fielding; Alison D Grant; Neil A Martinson; Gavin J Churchyard; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Andrew F Auld; Francisco Mbofana; Ray W Shiraishi; Mauro Sanchez; Charity Alfredo; Lisa J Nelson; Tedd Ellerbrock Journal: PLoS One Date: 2011-04-04 Impact factor: 3.240